Molecular diagnostics company Co-Diagnostics, Inc. raised USD 1.33 million for tuberculosis (TB) and USD 987,000 for human papillomavirus (HPV) tests in grants awarded by the Bill & Melinda Gates Foundation.
The funding will support the development and completion of TB and HPV tests on Co-Diagnostics' Co-Dx PCR Home platform, intended for global markets prioritizing rapid treatment decisions for TB and HPV.
Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets advanced diagnostic technologies. Its Co-Dx PCR Home platform utilizes nucleic acid detection and analysis to create tests for infectious diseases, including Covid-19. The company aims to make high-quality and affordable diagnostics more accessible globally.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.